Sunday , October 17 2021

OSE IMMUNOTHERAPEUTICS: Patent Issuance in Canada and Grant Agreement in the United States

Immunotherapeutics strengthens the industrial property of FR104 Phase 2 Clinical Development Immunotherapy with a Canadian Intellectual Property Office (CIPO) Patent Award Protecting the Product and Its Therapeutic Applications in T-cell-mediated autoimmune diseases in chronic inflammatory diseases and in transplants.

In addition, a patent protection agreement of the US Patent and Trademark Office (USPTO) was introduced to protect the use of the product in the treatment of chronic inflammatory diseases mediated by T cells.
FR104 and its therapeutic applications in autoimmune diseases, chronic inflammatory diseases and transplants are now patented in Europe, Japan, the United States and Canada, which strengthens intellectual protection and product value.
"These new protections from Canada and the United States significantly strengthen the FR104's international patent protection and strengthen its position as a key product in our portfolio of autoimmune diseases." clinical and biological tolerance and early signs of clinical efficacy, FR104 is ready to enter clinical phase 2 with a high potential for development in several autoimmune diseases. We are exploring the best options for further development, including opportunities for a global partnership, "commented Alexis Peyroles, General Manager, OSE Immunotherapeutics.

Copyright 2019 AOF
All rights of reproduction and representation reserved (Legal notice)

Source link